Irynotekan (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Irynotekan" in Polish language version.

refsWebsite

Global rank Polish rank

4^th place

7^th place

2^nd place

6^th place

low place

low place

4,294^th place

205^th place

7^th place

29^th place

447^th place

1,118^th place

low place

low place

doi.org

Lamb YN, Scott LJ. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. „Drugs”, 2017 Apr 11. DOI: 10.1007/s40265-017-0741-1. [dostęp 2017-04-13]. (ang.).
Innocenti F, Undevia SD, Iyer L, i wsp.. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. „J. Clin. Oncol.”. 22 (8), s. 1382–1388, kwiecień 2004. DOI: 10.1200/JCO.2004.07.173. PMID: 15007088.
O’Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. „J. Clin. Oncol.”. 24 (28), s. 4534–4538, październik 2006. DOI: 10.1200/JCO.2006.07.3031. PMID: 17008691.

drugbank.ca

Irinotecan, [w:] DrugBank [online], University of Alberta, DB00762 (ang.).

fda.gov

accessdata.fda.gov

FDA Review Letter http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/20571s8ltr.pdf.

jco.org

Innocenti F, Undevia SD, Iyer L, i wsp.. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. „J. Clin. Oncol.”. 22 (8), s. 1382–1388, kwiecień 2004. DOI: 10.1200/JCO.2004.07.173. PMID: 15007088.
O’Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. „J. Clin. Oncol.”. 24 (28), s. 4534–4538, październik 2006. DOI: 10.1200/JCO.2006.07.3031. PMID: 17008691.

nih.gov

ncbi.nlm.nih.gov

Lamb YN, Scott LJ. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. „Drugs”, 2017 Apr 11. DOI: 10.1007/s40265-017-0741-1. [dostęp 2017-04-13]. (ang.).
Innocenti F, Undevia SD, Iyer L, i wsp.. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. „J. Clin. Oncol.”. 22 (8), s. 1382–1388, kwiecień 2004. DOI: 10.1200/JCO.2004.07.173. PMID: 15007088.
Jong F, Maja J, de Jonge A, i wsp.. Role of pharmacogenetics in irinotecan therapy. „Cancer Lett.”. 234 (1), s. 90–106, marzec 2006. PMID: 16343744.
O’Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. „J. Clin. Oncol.”. 24 (28), s. 4534–4538, październik 2006. DOI: 10.1200/JCO.2006.07.3031. PMID: 17008691.

pubchem.ncbi.nlm.nih.gov

Irinotecan, [w:] PubChem [online], United States National Library of Medicine, CID: 60838 (ang.).
Irinotecan hydrochloride, [w:] ChemIDplus [online], United States National Library of Medicine [dostęp 2016-04-28] (ang.).

nytimes.com

New York Times Article http://www.nytimes.com/1996/06/18/science/new-cancer-drug-approved.html.

pfizer.com

labeling.pfizer.com

Camptosar® irinotecan hydrochloride injection August 2010 http://labeling.pfizer.com/ShowLabeling.aspx?id=533.